Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
19
11
2018
accepted:
05
06
2019
pubmed:
7
6
2019
medline:
28
4
2021
entrez:
8
6
2019
Statut:
ppublish
Résumé
Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly intervals from newly diagnosed lower-risk myelodysplastic syndromes patients in 16 European countries and Israel. Data on the transfusion dose density - the cumulative dose received at the end of each interval divided by the time since the beginning of the interval in which the first transfusion was received - were analyzed using proportional hazards regression with time-varying co-variates, with death and progression to higher-risk MDS/acute myeloid leukemia as events. Of the 1,267 patients included in the analyses, 317 died without progression; in 162 patients the disease had progressed. PFS was significantly associated with age, EQ-5D index, baseline World Health Organization classification, bone marrow blast count, cytogenetic risk category, number of cytopenias, and country. Transfusion dose density was inversely associated with PFS (
Identifiants
pubmed: 31171638
pii: haematol.2018.212217
doi: 10.3324/haematol.2018.212217
pmc: PMC7049377
doi:
Banques de données
ClinicalTrials.gov
['NCT00600860']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
632-639Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Am J Hematol. 2017 Jun;92(6):508-514
pubmed: 28247421
Br J Haematol. 1997 Nov;99(2):344-51
pubmed: 9375752
J Int Med Res. 2011;39(5):1941-5
pubmed: 22117997
N Engl J Med. 2005 Sep 15;353(11):1135-46
pubmed: 16162884
Haematologica. 2018 Jan;103(1):69-79
pubmed: 29122992
Leuk Res. 2011 Jan;35(1):8-11
pubmed: 20692036
Ann N Y Acad Sci. 1998 Jun 30;850:191-201
pubmed: 9668540
N Engl J Med. 2005 Feb 10;352(6):536-8
pubmed: 15703418
Transfusion. 2006 Oct;46(10):1712-8
pubmed: 17002627
Blood. 2011 Oct 6;118(14):3765-76
pubmed: 21753188
Ann N Y Acad Sci. 2005;1054:118-23
pubmed: 16339657
Haematologica. 2011 Oct;96(10):1433-40
pubmed: 21659359
Am J Hematol. 2011 Mar;86(3):245-50
pubmed: 21328437
Br J Haematol. 2015 Aug;170(3):372-83
pubmed: 25907546
PLoS One. 2011;6(8):e23109
pubmed: 21886780
Ann Hematol. 2011 Jan;90(1):1-10
pubmed: 20938663
Blood. 2019 Mar 7;133(10):1020-1030
pubmed: 30404811
Blood. 2002 Oct 1;100(7):2292-302
pubmed: 12239137
Transfusion. 2008 Jul;48(7):1478-85
pubmed: 18482180
Blood. 2010 May 27;115(21):4284-92
pubmed: 20299509
Blood. 2011 Dec 15;118(25):6675-82
pubmed: 22021369
Haematologica. 2016 Jan;101(1):38-45
pubmed: 26385212
Haematologica. 2012 Sep;97(9):1364-71
pubmed: 22419577
Transfus Med Rev. 2018 Apr;32(2):77-88
pubmed: 29526337
Haematologica. 2013 Mar;98(3):420-3
pubmed: 23300182
J Clin Oncol. 2007 Aug 10;25(23):3503-10
pubmed: 17687155
Eur J Haematol. 2007 Dec;79(6):463-7
pubmed: 17976187
Ann Hematol. 2013 Dec;92(12):1617-23
pubmed: 23842708
J Clin Oncol. 2010 Jun 10;28(17):2847-52
pubmed: 20421543
Adv Clin Exp Med. 2016 Jul-Aug;25(4):633-41
pubmed: 27629836
J Clin Invest. 2017 Jan 3;127(1):375-382
pubmed: 27941245
Blood. 2014 Aug 7;124(6):873-81
pubmed: 24923296
BMJ Open. 2015 Apr 03;5(4):e006048
pubmed: 25841232
Br J Haematol. 2010 May;149(3):322-33
pubmed: 20067561
J Clin Oncol. 2005 Oct 20;23(30):7594-603
pubmed: 16186598
Leukemia. 2015 Feb;29(2):259-68
pubmed: 25394715
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730